5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Nabriva Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2022 was 608.43%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Nabriva Therapeutics's 5-Year ROIIC % or its related term are showing as below:
NBRVF's 5-Year ROIIC % is ranked better than 93.42% of 1384
companies
in the Biotechnology industry
Industry Median: -19.27
vs NBRVF: 608.43
Nabriva Therapeutics 5-Year ROIIC % Historical Data
The historical data trend for Nabriva Therapeutics's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nabriva Therapeutics's 5-Year ROIIC %
For the Biotechnology subindustry, Nabriva Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nabriva Therapeutics's 5-Year ROIIC % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Nabriva Therapeutics's 5-Year ROIIC % falls into.
Nabriva Therapeutics 5-Year ROIIC % Calculation
Nabriva Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Nabriva Therapeutics 5-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Nabriva Therapeutics's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Nabriva Therapeutics (Nabriva Therapeutics) Business Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBRVF has been successfully added to your 